Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review

Henrique, Iara Carolina Barbosa; Lima, Tácio de Mendonça; Melo, Daniela Oliveira de; Aguiar, Patrícia Melo

doi:10.1111/jcpt.13034

Cited by 2 publications

(2 citation statements)

References 47 publications

(554 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found very limited evidence focusing on the cost-effectiveness of antipsychotics in this population. Though there are existing reviews of the cost-effectiveness of antipsychotics these cover wider populations [ 66 – 68 ]. As people with FEP are likely to respond differently compared to populations with more established conditions and given the variation in cost and side effect profiles of antipsychotics, more research is needed to identify which antipsychotics are most cost-effective in this group.…”

Section: Discussionmentioning

confidence: 99%

A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis

et al. 2022

View full text Add to dashboard Cite

Background Preventing psychotic disorders and effective treatment in first-episode psychosis are key priorities for the National Institute for Health and Care Excellence. This review assessed the evidence base for the cost-effectiveness of health and social care interventions for people at risk of psychosis and for first-episode psychosis. Methods Electronic searches were conducted using the PsycINFO, MEDLINE and Embase databases to identify relevant published full economic evaluations published before August 2020. Full-text English-language studies reporting a full economic evaluation of a health or social care intervention aiming to reduce or prevent symptoms in people at risk of psychosis or experiencing first-episode psychosis were included. Screening, data extraction, and critical appraisal were performed using pre-specified criteria and forms based on the NHS Economic Evaluation Database (EED) handbook and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist for economic evaluations. The protocol was registered on the PROSPERO database (CRD42018108226). Results were summarised qualitatively. Results Searching identified 1,628 citations (1,326 following the removal of duplications). After two stages of screening 14 studies met the inclusion criteria and were included in the review. Interventions were varied and included multidisciplinary care, antipsychotic medication, psychological therapy, and assertive outreach. Evidence was limited in the at-risk group with only four identified studies, though all interventions were found to be cost-effective with a high probability (> 80%). A more substantial evidence base was identified for first-episode psychosis (11 studies), with a focus on early intervention (7/11 studies) which again had positive conclusions though with greater uncertainty. Conclusions Study findings generally concluded interventions were cost-effective. The evidence for the population who are at-risk of psychosis was limited, and though there were more studies for the population with first-episode psychosis, limitations of the evidence base (including generalisability and heterogeneity across the methods used) affect the certainty of conclusions.

show abstract

Section: Discussionmentioning

confidence: 99%

A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Though there exist studies reviewed the economic evaluation of treatment for schizophrenia ( 8 – 10 , 77 ), few fully discussed the treatment sequences, AEs, compliance and persistence of the included studies. Thus, this review provides more comprehensive and detailed information of modeling methodology for economic evaluation.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia

Wang

Shi

Guan

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Background: Schizophrenia is a severe and complex disease with substantial economic and social burdens. Despite multiple treatment choices, adverse events, and impaired social functions are still challenges in clinical therapy. Pharmacoeconomic evaluations could provide evidence to help decision makers improve the utilization of scarce resources. However, there remains some challenges especially in modeling due to uncertainties in progression of schizophrenia. There are limited summaries about the overall methodologies of schizophrenia economic evaluations.Objective: The aim of this study is to review the existing economic evaluations of antipsychotics for the treatment of schizophrenia and summarize the evidence and methods applied.Methods: An electronic literature search was performed in PubMed, Web of Science, EBSCO host, The Cochrane Library and ScienceDirect from January 2014 to December 2020. Search terms included “schizophrenia,” “schizophrenic,” “pharmacoeconomic,” “economic evaluation,” “cost-effectiveness,” and “cost-utility.” The Literature was screened and extracted by two researchers independently and assessed with the Quality of Health Economic Studies (QHES) List and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement.Results: A total of 25 studies were included in the review. The regions included Europe, North America, Asia and Africa. Most of the studies chose second-generation antipsychotics as comparators and integrated treatment sequences. Time horizons varied from 1 year to lifetime. The healthcare sector was the most common perspective, accordingly, most of the evaluations considered only direct medical costs. The Markov model and decision tree model were the most common choices. Adverse events, compliance and persistence were considered important parameters. Quality-adjusted life-years were the major outcomes applied to the economic evaluations. All utilities for health states and adverse events were collected from published literature. All of the studies applied uncertainty analysis to explore the robustness of the results. The quality of the studies was generally satisfactory. However, improvements were needed in the choice of time horizons, the measurements of outcomes and the descriptions of assumptions.Conclusions: This study highlights the methodology of economic evaluation of schizophrenia. Recommendations for modeling method and future study are provided.

show abstract

Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review

Cited by 2 publications

References 47 publications

A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis

A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis

A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia

Contact Info

Product

Resources

About